MedTrace Logo

Efficacy of Tildrakizumab in Difficult-to-treat Areas in Psoriasis

NCT05938361 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2025-09-24

No results posted yet for this study

Summary

Psoriasis is a chronic inflammatory disease that affects between 2% and 4% of the French population.Some specific localizations are more difficult to manage, such as the scalp, nails, genital region and palmoplantar localizations.

Tildrakizumab, an anti-interleukin-23 (IL-23) monoclonal antibody, has demonstrated efficacy and safety in the treatment of patients with moderate to severe psoriasis.

Real-life data on the efficacy of Tildrakizumab in unselected patients with these difficult-to-treat locations are still limited.

The aim of the ZODIPSO study is to evaluate the efficacy and safety of Tildrakizumab in patients presented difficult to treat locations in psoriasis : nail, scalp, genital and palmoplantar.

The main objective is to assess the overall response and the specific response to Tildrakizumab at these specific areas up to W52.

Conditions

  • Psoriasis Palmaris
  • Psoriasis Genital
  • Psoriasis of Scalp
  • Psoriasis Plantaris
  • Psoriasis Nail

Interventions

OTHER

Psoriasis clinical assessments

Global evaluation of psoriasis and specific evaluation by areas

OTHER

Quality of life evaluation

DLQI questionnaire at each visit

OTHER

Satisfaction assessment

Visual analogic scale at W16, W28, W52

OTHER

Pruritus evaluation

Visual analogic scale at each visit

Sponsors & Collaborators

  • Clin4all

    lead NETWORK

Principal Investigators

  • Ines ZARAA, MD · Saint Joseph hospital Paris

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-01
Primary Completion
2024-11-01
Completion
2025-10-15

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05938361 on ClinicalTrials.gov